---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-25-000035"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:27:11.369187+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027

## Summary
- Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.
- Cash & investments $373.1M; cash runway into 2H 2026; 2025 guidance: ~$170M cash burn.
- ALPHA3 pivotal trial for cema-cel in 1L LBCL: 40 sites activated; futility analysis mid-2025; primary EFS data YE2026.
- ALLO-329 autoimmune: IND cleared; RESOLUTION basket trial start mid-2025; proof-of-concept data YE2025.
- ALLO-316 RCC: Phase 1b expansion fully enrolled; data mid-2025; RMAT designation received.

## SEC filing metadata
- accession: 0001737287-25-000035
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000035/0001737287-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000035/allo-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-25-000035
- JSON: https://secwatch.observer/filing/0001737287-25-000035.json
- Plain text: https://secwatch.observer/filing/0001737287-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.